Molecular markers and death from prostate cancer.
Concato J, Jain D, Uchio E, Risch H, Li WW, Wells CK. Molecular markers and death from prostate cancer. Annals Of Internal Medicine 2009, 150: 595-603. PMID: 19414838, DOI: 10.7326/0003-4819-150-9-200905050-00005.Peer-Reviewed Original ResearchConceptsProstate-specific antigen levelProstate cancerLong-term riskAntigen levelsMicrovessel densityMedian prostate-specific antigen levelIncreased long-term riskVeterans Affairs Healthcare SystemIncident prostate cancerObservational cohort studyProportional hazards analysisTime of diagnosisHigher microvessel densityVeterans Health AdministrationBcl-2Years of ageProstate cancer biopsiesClinical care recordsClinical characteristicsCohort studyPatient ageMedian ageComorbid conditionsHistologic gradeResidual confoundingLack of Immunohistochemical Detection of VEGF in Prostate Carcinoma
Kamath A, Helie M, Bifulco CB, Li WW, Concato J, Jain D. Lack of Immunohistochemical Detection of VEGF in Prostate Carcinoma. Applied Immunohistochemistry & Molecular Morphology 2009, 17: 227-232. PMID: 19098681, DOI: 10.1097/pai.0b013e31818f9e7f.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAntibodiesHumansImmunohistochemistryMaleProstatic HyperplasiaProstatic NeoplasmsVascular Endothelial Growth Factor AConceptsVascular endothelial growth factorVEGF expressionBenign glandsMalignant glandsDifferent antigen retrieval techniquesVeterans Health Administration hospitalsEndothelial cellsBenign prostatic hyperplasiaRenal cell carcinomaDifferent antibodiesNonspecific stainingPotential therapeutic targetEndothelial growth factorCell carcinomaProstatic hyperplasiaAntigen retrieval methodAntigen retrieval techniqueFibromuscular stromaAdministration HospitalBreast carcinomaProstatic adenocarcinomaHepatocellular carcinomaProstate carcinomaStudy populationIHC analysis